Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report
Abstract Background Programmed cell death 1 (PD-1) and its ligand 1 (PD-L1) inhibitors have quickly become standard of care for patients with advanced non-small cell lung cancer and increasing numbers of other cancer types. In this report, we discuss the clinical history, pathological evaluation, an...
Main Authors: | Hong Li, Weijie Ma, Ken Y. Yoneda, Elizabeth H. Moore, Yanhong Zhang, Lee L. Q. Pu, Garrett M. Frampton, Michael Molmen, Philip J. Stephens, Tianhong Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-02-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13045-017-0433-z |
Similar Items
-
Severe Pneumonitis after Nivolumab Treatment Accompanied by Acute Pulmonary Embolism in a Patient with Lung Adenocarcinoma
by: Ji-Ping Liao, et al.
Published: (2017-01-01) -
Case Report. Extracorporeal Membrane Oxygenation in Nivolumab Associated Pneumonitis
by: Schneider Thomas-Michael, et al.
Published: (2017-04-01) -
Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis
by: Cui P, et al.
Published: (2017-09-01) -
Nivolumab for Metastatic Urothelial Cancer in a Renal Allograft Recipient With Subsequent Graft Rejection and Treatment Complete Remission: A Case Report
by: Didi Chen, et al.
Published: (2021-05-01) -
High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review
by: N. Koyama, et al.
Published: (2018-01-01)